It may be overbought in the short term but it is w

Quote:

---

It may be overbought in the short term but it is way undervalued. Some $$ in the coffer from a product sale or partnership will sure cure the overbought scenario.

---

I agree with Chris, we are wayyyyyyyyyyyyyy undervalued (STILL)!

Don't look surprised if we gap up to $20 or so on a partnership deal or a product sale or diagnotisic division spin off etc..

The analyst with his reaffirmed target price of $45 is realistic in my book.

I don't know where we will go to with the PPS after significant news is announced but i'm very confident it will be between $5 and $40

Remember Gerald stated we will grow organically and then uplist to the NASDAQ, so that means we will get back to at least $4 (or else you can't uplist).

Seeing how confident Gerald is tweeting away lately i would say something is already set in stone.

And keep in mind that once your on the NASDAQ, institutes will buy AMBS because it is undervalued and should be worth around a $300m marketcap.

Last time i checked our marketcap was around $10m i believe?

Well i'm off to bed, have a good night!